Profile data is unavailable for this security.
About the company
Vericel Corporation is a fully-integrated, commercial-stage biopharmaceutical company. The Company is a provider of advanced therapies for the sports medicine and severe burn care markets. It markets three products in the United States. MACI (autologous cultured chondrocytes on porcine collagen membrane) is an autologous-cellularized scaffold product indicated for the repair of symptomatic, single or multiple full-thickness cartilage defects of the knee with or without bone involvement in adults. Epicel (cultured epidermal autografts) is a permanent skin replacement for the treatment of patients with deep dermal or full thickness burns greater than or equal to 30% of total body surface area. The Company also holds a license for North American rights to NexoBrid (anacaulase-bcdb), a biological orphan product containing proteolytic enzymes, which is indicated for the removal of eschar in adults with deep partial-thickness and/or full-thickness burns.
- Revenue in USD (TTM)197.52m
- Net income in USD-3.18m
- Incorporated1989
- Employees314.00
- LocationVericel Corp64 Sidney StCAMBRIDGE 02139-4170United StatesUSA
- Phone+1 (734) 930-5555
- Fax+1 (734) 665-0485
- Websitehttps://vcel.com/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Amphastar Pharmaceuticals Inc | 644.40m | 137.55m | 2.00bn | 1.76k | 15.78 | 3.07 | 11.24 | 3.10 | 2.59 | 2.59 | 12.16 | 13.30 | 0.5716 | 2.78 | 6.33 | 365,925.60 | 12.38 | 9.42 | 14.42 | 11.56 | 54.91 | 47.83 | 21.65 | 15.23 | 1.70 | 10.68 | 0.4799 | 0.00 | 29.14 | 16.94 | 50.51 | -- | -4.00 | -- |
| Rocket Pharmaceuticals Inc | 0.00 | -245.60m | 2.00bn | 268.00 | -- | 4.05 | -- | -- | -2.94 | -2.94 | 0.00 | 5.46 | 0.00 | -- | -- | 0.00 | -43.93 | -35.26 | -47.67 | -37.49 | -- | -- | -- | -- | -- | -- | 0.0412 | -- | -- | -- | -10.70 | -- | 62.52 | -- |
| Kymera Therapeutics Inc | 78.59m | -146.96m | 2.04bn | 187.00 | -- | 4.69 | -- | 25.93 | -2.52 | -2.52 | 1.35 | 7.11 | 0.1333 | -- | 7.38 | 420,278.10 | -24.93 | -23.03 | -28.76 | -27.64 | -- | -- | -186.99 | -207.82 | -- | -- | 0.0065 | -- | 67.84 | -- | 5.07 | -- | 91.01 | -- |
| Dyne Therapeutics Inc | 0.00 | -235.94m | 2.04bn | 141.00 | -- | 15.95 | -- | -- | -3.94 | -3.94 | 0.00 | 1.49 | 0.00 | -- | -- | 0.00 | -100.10 | -52.81 | -120.31 | -57.45 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -40.36 | -- | 40.32 | -- |
| Guardant Health Inc | 563.95m | -479.45m | 2.09bn | 1.78k | -- | 13.15 | -- | 3.70 | -4.28 | -4.28 | 5.04 | 1.30 | 0.3321 | 4.00 | 6.06 | 317,002.80 | -28.23 | -22.26 | -31.99 | -24.59 | 59.74 | 64.62 | -85.02 | -97.07 | 6.24 | -12.04 | 0.8778 | -- | 25.45 | 44.14 | 26.76 | -- | 0.2786 | -- |
| Geron Corp | 237.00k | -184.13m | 2.09bn | 141.00 | -- | 7.82 | -- | 8,816.07 | -0.3246 | -0.3246 | 0.0004 | 0.455 | 0.0008 | -- | 0.0988 | 1,680.85 | -62.99 | -51.32 | -92.09 | -64.90 | -- | -- | -77,690.72 | -19,949.13 | -- | -- | 0.2484 | -- | -60.23 | -25.97 | -29.76 | -- | 120.29 | -- |
| Vera Therapeutics Inc | 0.00 | -95.99m | 2.11bn | 51.00 | -- | 16.91 | -- | -- | -2.28 | -2.28 | 0.00 | 2.29 | 0.00 | -- | -- | 0.00 | -62.54 | -- | -74.10 | -- | -- | -- | -- | -- | -- | -- | 0.3291 | -- | -- | -- | -7.79 | -- | -- | -- |
| Denali Therapeutics Inc | 330.53m | -145.22m | 2.13bn | 445.00 | -- | 2.01 | -- | 6.45 | -1.09 | -1.09 | 2.39 | 7.45 | 0.2529 | -- | -- | 742,766.30 | -11.11 | -14.98 | -13.37 | -17.71 | -- | -- | -43.94 | -104.50 | -- | -- | 0.00 | -- | 204.74 | 20.67 | 55.45 | -- | 30.70 | -- |
| TG Therapeutics Inc | 233.66m | 12.67m | 2.15bn | 264.00 | 985.13 | 13.12 | 166.73 | 9.19 | 0.0141 | 0.0141 | 1.61 | 1.06 | 0.8933 | -- | 9.15 | 885,087.10 | 4.84 | -62.87 | 6.09 | -80.06 | 93.95 | -- | 5.42 | -405.03 | 5.18 | 1.64 | 0.3842 | -- | 8,290.02 | 333.86 | 106.39 | -- | -- | -- |
| Arvinas Inc | 78.50m | -367.30m | 2.16bn | 445.00 | -- | 3.26 | -- | 27.50 | -6.62 | -6.62 | 1.45 | 9.71 | 0.061 | -- | 157.00 | 176,404.50 | -28.35 | -22.01 | -36.10 | -26.47 | -- | -- | -464.71 | -316.55 | -- | -- | 0.0012 | -- | -40.26 | 40.53 | -30.02 | -- | 0.4852 | -- |
| Vericel Corp | 197.52m | -3.18m | 2.20bn | 314.00 | -- | 9.62 | 1,403.25 | 11.13 | -0.0684 | -0.0684 | 4.15 | 4.72 | 0.6304 | 4.26 | 3.77 | 629,031.90 | -1.02 | -3.07 | -1.17 | -3.50 | 68.64 | 67.87 | -1.61 | -4.49 | 4.21 | -- | 0.0004 | -- | 20.17 | 16.80 | 80.96 | -- | 59.35 | -- |
| Avidity Biosciences Inc | 9.56m | -212.22m | 2.26bn | 253.00 | -- | 3.77 | -- | 236.67 | -2.90 | -2.90 | 0.131 | 6.32 | 0.0151 | -- | -- | 37,786.56 | -33.49 | -31.61 | -37.40 | -34.45 | -- | -- | -2,219.88 | -1,540.50 | -- | -- | 0.00 | -- | 3.64 | 90.71 | -21.97 | -- | 143.89 | -- |
| Corcept Therapeutics Incorporated | 482.38m | 106.14m | 2.31bn | 352.00 | 23.28 | 4.53 | 21.52 | 4.78 | 0.9542 | 0.9542 | 4.32 | 4.90 | 0.8007 | 0.9374 | 13.37 | 1,370,384.00 | 17.62 | 21.17 | 20.65 | 23.85 | 98.66 | 98.52 | 22.00 | 27.23 | 4.31 | -- | 0.00 | 0.00 | 20.04 | 13.93 | 4.66 | 7.08 | -14.15 | -- |
| Rhythm Pharmaceuticals Inc | 77.43m | -184.68m | 2.33bn | 226.00 | -- | 13.35 | -- | 30.04 | -3.19 | -3.19 | 1.34 | 2.86 | 0.2165 | 1.61 | 7.34 | 342,601.80 | -51.64 | -47.21 | -59.55 | -52.84 | 87.99 | -- | -238.52 | -681.38 | 5.43 | -- | 0.3847 | -- | 227.56 | -- | -1.97 | -- | -42.10 | -- |
| Celldex Therapeutics, Inc. | 6.88m | -141.43m | 2.34bn | 160.00 | -- | 4.72 | -- | 339.28 | -2.91 | -2.91 | 0.1421 | 7.68 | 0.0168 | -- | 4.63 | 43,018.75 | -34.56 | -29.65 | -36.80 | -31.42 | -- | -- | -2,054.76 | -1,747.94 | -- | -- | 0.00 | -- | 192.02 | -6.32 | -25.91 | -- | 17.46 | -- |
| CG Oncology Inc | 204.00k | -67.80m | 2.41bn | 61.00 | -- | -- | -- | 11,824.67 | -1.07 | -1.07 | 0.0032 | 2.91 | -- | -- | -- | 3,344.26 | -- | -- | -- | -- | -- | -- | -23,826.96 | -- | -- | -- | 0.002 | -- | 6.81 | -- | -54.83 | -- | -- | -- |
Data as of Apr 25 2024. Currency figures normalised to Vericel Corp's reporting currency: US Dollar USD
62.72%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| BlackRock Fund Advisorsas of 31 Dec 2023 | 7.29m | 15.07% |
| Brown Capital Management LLCas of 31 Dec 2023 | 6.82m | 14.09% |
| The Vanguard Group, Inc.as of 31 Dec 2023 | 3.25m | 6.71% |
| RTW Investments LPas of 31 Dec 2023 | 3.21m | 6.64% |
| SSgA Funds Management, Inc.as of 31 Dec 2023 | 2.66m | 5.51% |
| Conestoga Capital Advisors LLCas of 31 Dec 2023 | 2.34m | 4.84% |
| GW&K Investment Management LLCas of 31 Dec 2023 | 1.32m | 2.74% |
| Morgan Stanley & Co. LLCas of 31 Dec 2023 | 1.16m | 2.39% |
| Macquarie Investment Management Business Trustas of 31 Dec 2023 | 1.15m | 2.37% |
| Loomis, Sayles & Co. LPas of 31 Dec 2023 | 1.14m | 2.36% |
More ▼
Data from 31 Dec 2023 - 31 Dec 2023Source: FactSet Research Systems Inc.
